GSK plc (NYSE: GSK) price spikes 16% after Zantac lawsuit gets tossed

GSK share price spiked as a US court ruled in its favor in the Zantac case

NEW DELHI (CoinChapter.com) — GSK Plc’s (NYSE: GSK) stock price rose to a new multi-month high of $39.74 on Dec 7 after jumping 16% from its intraday low of $34.2, its best daily performance since March 2020.

The rally came in response to the news of a US Federal judge rejecting thousands of lawsuits against the company’s heartburn drug Zantac. Meanwhile, from a technical perspective, GSK stock price eyes a bullish continuation toward its interim resistance near $39, as shown below.

GSK plc (NYSE: GSK) price chart with RSI. Source: TradingvView.com

Furthermore, GSK’s relative strength index became overbought, currently clocking at 77.92 on the daily charts. Overbought RSI levels often precede trend reversals. GSK stock price has been rising since Nov 11.

If GSK stocks start falling, they might fall to test support near $37. Moreover, continued sell-off could force GSK stock price to drop to $34.9 before recovering.

Judge Says Zantac Suit Against GSK “Based On Flawed Science”

The dismissal by Judge Robin Rosenberg in Florida handed pharmaceutical companies GSK, Pfizer, Sanofi, and Boehringer Ingelheim a big win. In his order, Judge Rosenberg said that the nearly 2,500 lawsuits against the companies were based on flawed science.

However, the judge said that the only reliable testing of Zantac showed an “unprovable risk of cancer.”

Also Read: Ethereum Price Could Restart Increase If This Key Support Plays Well

In detail, Zantac is the brand name for ranitidine, a heartburn medication. Several pharmaceutical companies, including GSK, Pfizer, and Sanofi, have sold the drug over the past 35 years.

The judge ruled that the expert witnesses that the plaintiffs had brought forward used “unreliable methodologies” and did not objectively evaluate the data surrounding the drug. Additionally, Judge Rosenberg noted that no scientist outside the litigation concluded that ranitidine might cause cancer.

Meanwhile, the plaintiffs’ lawyers hit out against the verdict, calling it a “miscarriage of justice.”

The firms might still face several personal injury cases filed in state courts.

Reserve Bank of India has raised its repo rate. Here’s what it means.

Recent Posts

Why ADA Price Is Up Today?

The recent Federal Open Market Committee (FOMC) decision, along with some technical cues, could be…

21 hours ago

Sui Turns One: Debut Year of Growth and Tech Breakthroughs Puts Sui at Forefront of Web3

Grand Cayman, Cayman Islands, May 3rd, 2024, ChainwireProtocol launches, growth trajectory, and industry-leading technology point…

23 hours ago

Top VCs Join EYWA’s Seed Round Led by Curve Founder

EYWA, a consensus bridge that secures transactions across multiple protocols, has raised a total of…

1 day ago

StakingFarm Expands Crypto Frontier with Launch of Innovative Bitcoin Staking Platform

StakingFarm is proud to announce the launch of its groundbreaking Bitcoin liquid staking product, a pioneering…

1 day ago

Blockchain Asset Management LLC Launches Exclusive Blockchain Fund for Accredited Investors

Rahaman Kargar, founder of Blockchain Asset Management, proudly announces the launch of its blockchain fund tailored…

1 day ago

OriginTrail Decentralized Knowledge Graph for trusted cross-organization real-time data integration in EU-funded DMaaST

Trace Labs, the core developers of OriginTrail, has joined the European Union's initiative to foster a…

1 day ago